Novogene Europe Bolsters Genomic Sequencing Capabilities with Fifth NovaSeq X Plus System in Europe
[City, Country] – July 3, 2025 – Novogene Europe, a leading provider of genomic sequencing services, is pleased to announce a significant expansion of its European operational capacity with the installation of its fifth Illumina NovaSeq™ X Plus sequencing system. This strategic investment underscores Novogene’s commitment to meeting the growing demand for high-throughput, high-resolution genomic data across the continent.
The addition of this state-of-the-art sequencing instrument marks a pivotal moment for Novogene Europe, enabling the company to further enhance its ability to serve a diverse range of clients, from academic research institutions to pharmaceutical and biotechnology companies. The NovaSeq X Plus system represents the pinnacle of Illumina’s sequencing technology, offering unparalleled throughput, exceptional accuracy, and a cost-effective solution for large-scale genomic projects.
“We are thrilled to announce the deployment of our fifth NovaSeq X Plus system in Europe,” said [Name and Title of Novogene Europe Representative, e.g., Dr. Jianwen Ji, CEO of Novogene Europe]. “This expansion is a direct response to the increasing need for advanced sequencing capabilities within the European research and development landscape. By augmenting our infrastructure, we are reinforcing our position as a trusted partner for delivering high-quality, large-scale genomic data, thereby accelerating scientific discovery and therapeutic innovation.”
The NovaSeq X Plus system is designed to deliver up to 25,000 whole human genomes per year, significantly increasing the volume of data Novogene Europe can process. This enhanced capacity will empower researchers to undertake more ambitious projects, driving progress in areas such as precision medicine, rare disease research, cancer genomics, and infectious disease surveillance.
Novogene Europe’s commitment to technological advancement and customer service remains paramount. The company’s comprehensive suite of services, coupled with its expanded sequencing capacity, provides clients with a robust platform for their genomic research needs. This investment ensures that Novogene Europe is well-equipped to support the evolving demands of the European life sciences sector, fostering collaboration and driving impactful scientific breakthroughs.
This expansion represents a significant step forward in Novogene’s mission to provide cutting-edge genomic solutions and contribute to the advancement of human health and scientific understanding across Europe.
About Novogene Europe:
Novogene is a global leader in genomic sequencing services, offering a comprehensive portfolio of advanced sequencing solutions and bioinformatics support. With a commitment to innovation and quality, Novogene empowers researchers worldwide to accelerate discoveries in genomics, transcriptomics, and epigenomics. Novogene Europe serves as a key hub, providing localized expertise and cutting-edge technology to the European scientific community.
Novogene Europe étend ses capacités de séquençage avec un cinquième système NovaSeq X Plus en Europe
AI has delivered the news.
The answer to the following question is obtained from Google Gemini.
PR Newswire Healthring published ‘Novogene Europe étend ses capacités de séquençage avec un cinquième système NovaSeq X Plus en Europe’ at 2025-07-03 09:00. Please write a detailed article about this news in a polite tone with relevant information. Please reply in English with the article only.